Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
- Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
- Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
- Sumitomo Splits Non-Pharma “Frontier” Business
May 13, 2024
- Shionogi Nabs Global Rights to Maze’s Pompe Disease Therapy
May 13, 2024
- Amgen Files Otezla for Palmoplantar Pustulosis in Japan
May 13, 2024
- Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
- Jardiance Positive in Japanese CKD Patients Too: Subgroup Analysis
May 10, 2024
- Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
- Japan Ethical Drug Sales Down 2.4% in March: Crecon
May 10, 2024
- Keytruda Best-Selling Drug in Japan for 7th Month in April: Encise
May 10, 2024
- Ono CEO Calls for Full Abolition of Spillover Re-Pricing Rule
May 10, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
- Chugai Launches Decentralized PI Trial for Cancer Drug Tobemstomig
May 9, 2024
- Organon to Take Over Japan Rights to Migraine Drug Maxalt in July
May 9, 2024
- Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
- Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
- Renalys, Japan Kidney Association Join Hands to Develop Innovative Therapies
May 8, 2024
- Santen, Mitsubishi Tanabe to Copromote Alesion Eyelid Cream in Japan
May 8, 2024
- Astellas, Poseida Expand Collab in Off-the-Shelf Cell Therapies for Cancer
May 7, 2024
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…